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Abstract. The effect produced by repeated administration of the HI-antihistaminics 
diphenhydramine, promethazine and pyrilamine on their ability to induce antinociception was 
evaluated :Ln the mouse hot-plate and abdominal constriction tests. Contrary to morphine, 
baclofen and oxotremorine, the three HI antagonists investigated did not promote the 
devetopment of tolerance to the analgesiceffect after 14 days of repeated treatment. HI 
antagonists, could, therefore, represent apromising pharmacological approach to the management 
of chronic Ipain. 1998 Elsevier Science Inc. 
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Introduction 
The HI-receptor antagonists are among the most widely used medications in the world. 
Antagonists of histamine H1 receptors produce, in addition to the welt known peripheral effects, 
various central inhibitory actions (Simons and Simons, 1994). Antihistamines have been shown 
to be analgesic adjuvants in both animal and human studies. They are widely used as adjuvants 
in preoperative analgesia as well as in postoperative pain and cancer pain (Sunshine et al., 1987). 
Clinically, ‘hydroxyzine decreases the amount of narcotic that is necessary, provides sedating, 
and other antihistaminic effects that are helpful in certain ctinical situations. Furthermore, 
hydroxyzine itself has some analgesiceffect (Beaver and Freise, 1976). More recently it has 
been observed that some other antihistaminics, such as diphenhydramine, pyrilamine and 
promethazine, are endowed with analgesicproperties in both laboratory animals (Rumore and 
Schtichting, 1985)and humans (Campos and SoIis, 1980). 
Long-term administration of HI antagonists does not lead to autoinduction of epathic 
metabolism or increase their elimination rate (Simons et al., 1988). In studies lasting 4-12 weeks 
during which compliance was closely monitored, peripheral HI receptor blockade in the skin and 
el%cacy against allergicrhinitis did not decrease markedly (Simons and Simons, 1994). On the 
other hand, the possibility that some central nervous system effects will develop tolerance to Hi 
antagonists over prolonged dosing is controversial (Levander et al., 1991; Goetz et al., 1989). 
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To throw some light onto the induction of tolerance in central effects to Ht antagonists, we 
investigated the ability of these compounds to enhance the pain threshold in mice after repeated 
administration. 
Methods and Materials 
Animals. Male Swiss albino mice (23-30 g) from Morini (San Polo d’Enza, Italy) breeding farm 
were used. Fifteen mice were housed per cage. The cages were placed in the experimental room 
24 h before the test for acclimatization. The animals were kept at 23+1”C with a 12 h light/dark 
cycle, light at 7 a.m., with food and water ad libitum. All experiments were carried out according 
to the guidelines of the European Community Council. 
Hot plate test. The method adopted was described by O’Callaghan and Holzman (1975). Mice 
were placed inside a stainless steel container, thermostatically set at 52.5 + O.l’C in a precision 
water-bath from KW Mechanical Workshop, Siena, Italy. Reaction times (s), were measured 
with a stop-watch before and at regular intervals up to a maximumof 60 min after treatment. 
The endpoint used was the licking of the fore or hind paws. Those mice scoring below 12 and 
over 18 s in the pretest were rejected (30%). An arbitrary cut-off time of 45 s was adopted. 
Abdominal constriction test. Mice were injected i.p. with a 0.6 % solution of acetic acid (10 
ml kg-‘), according to Koster et al. (1959). The number of stretching movements was counted for 
10 min, starting 5 min after acetic acid injection. 
Rota-rod test. The apparatus consisted of a base platform and a rotating rod of 3 cm diameter 
with a non-slippery surface. The rod was placed at a height of 15 cm from the base. The rod, 30 
cm in length, was divided into 5 equal sections by 6 disks. Thus, up to 5 mice were tested 
simultaneously on the apparatus, with a rod-rotating speed of 16 r.p.m. The integrity of motor 
coordination was assessed on the basis of the number of falls from the rod in 30 s accordingto 
Vaught et al. (1985). The performance time was measured before and 15, 30 and 45 min after 
treatment. 
Drugs. The following drugs were used: (&) baclofen (P-p-chlorophenyl GABA) (Sigma); 
pyrilatnine maleate, promethazine hydrochloride, oxotremorine sesquifumarate (RBI); morphine 
hydrochloride (USL 10/D Florence, Italy), diphenhydramine hydrochloride (De Angeli). All 
drugs were dissolved in isotonic (NaCI 0.9 %) saline solution immediately before use. Drug 
concentrations were prepared in such a way that the necessary dose could be administered in a 
volume of 10 ml kg-’ by subcutaneous (s.c.) and intraperitoneal (i.p.) route. 
Statistical analysis. Results are given as the mean do s.e.m.; analysis of variance (ANOVA), 
followed by Fisher’s PLSD procedure for post-hoc comparison, was used to verify the 
significancebetween two means. P values of less than 0.05 were considered significant. Data 
were analyzed with the StatView for the Macintosh computer program (1992). 
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Results 
The mouse hot-plate and abdominal constriction tests, involvingrespectively thermal and 
chemical stimuli were used to evaluate the potential development of tolerance, after repeated 
treatment, against the analgesia induced by pyrilamine (15 mg kg-1 s.c.), promethazine (6 mg kg-l 
s.c.) and diphenhydramine (20 mg kg1 s.c.). Acute administration (day 1) of the above 
mentioned compounds produced antinociception that peaked 15 min after injection (Fig. 1). The 
three Hl antagonists investigated, injected twice daily for 2 weeks (day 14), did not promote the 
development of tolerance to the analgesics in the mouse hot-plate test (Fig. 1). In the same 
experimental conditions, analgesic drugs with different mechanisms of action but endowed with 
the same efftcacy of the three Ht antagonists investigated, such as morphine (7 mg kg-* s.c.), 
baclofen (4 mg kg-* s.c.) and oxotremorine (100 pg kg-t s.c.), cause the development of complete 
tolerance to their analgesic activity (Fig. 1). 
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FIG. I 
Effect of repeated administration of pyrilamine, promethazine and 
diphenhydramine in comparison with morphine, oxotremorine and baclofen in 
the mouse hot-plate test. Licking latency was recorded in relation to the 
maximumanalgesic effect of each drug. *P<O.Ol, **P<O.OOl versus saline- 
treated mice 
PL-320 No Tolerance by Ht-antihistaminics Vol. 63, No. 22, 1998 
Diphenhydramine (20 mg kg-1 s.c.), pyrilamine (15 mg kg-1 s.c.) and promethazine (6 mg 
kg-t s.c.) were able to enhance the pain threshold also in the mouse abdominal constriction test 
(Fig. 2). Similarly to results with the mouse hot-plate test, the three Ht antagonists investigated 
did not cause tolerance to their analgesic activity. Instead, a reduction in the number of 
abdominal constrictions after repeated administration (day 14) equalled that produced after acute 
treatment ( day 1) (Fig. 2). Similarly to the hot-plate test, in the abdominal constriction test 
morphine (1 mg kg-1 s.c.), baclofen (2 mg kg-1 s.c.) and oxotremotine (100 pg kg’ s.c.) cause the 
development of complete tolerance to their analgesic activity (data not shown). 
The analgesic compounds used as reference drugs have been administered at doses, chosen 
by means of dose-response data, which are analgesically active to antihistamines. Doses of 
antihistamines used are the highest effective which do not produce behavioral side effects (data 
not shown). 
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FIG. 2 
Lack of development of tolerance to diphenhydramine, pyrilamine and 
promethazine in the mouse abdominal constriction test. All drugs were 
injected 15 min before the test. *P<O.OOl in comparison with saline- 
treated mice. 
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The analgesic drugs investigated, at the doses used, did not modify animals’ gross behavior. 
Moreover, repeated treatment with these compounds did not impair mouse motor coordination 
as revealed by the rota-rod test (Table 1). By contrast, repeated administration of morphine, 
baclofen and oxotremorine altered animal’s gross behavior and impaired motor coordination as 
evidenced t,y an increase of the number of falls of mice from the rotating rod, in comparison with 
saline-treated mice, in the rota-rod test (data not shown). 
TABLEl. 
Lack of $%ct of repeated administration to mice of pyrilamine, promethazine and 
diphenhydramine on the rota-rod test. 
TREATMENT NUMBER OF FALLS IN 30 s 
mg kg-1 S.C. pretest 15 min 30 min 45 min 
SALINE 3.7 * 0.4 2.2 * 0.4 1.2kO.2 0.9 + 0.2 
PYRILAMII~ 15 4.0 z!I 0.3 2.7 f 0.4 1.5f 0.3 0.7 + 0.2 
PROMETHAZINE 6 3.8 f 0.4 2.3 + 0.4 1.6f0.3 1 .o f 0.2 
DIPHENHYDRAMINE 20 3.5 + 0.5 2.1 + 0.3 1.4 + 0.2 1.1 + 0..3 
Discussion 
Chron:ic pain is one of the most difficult and perplexing patient problems encountered by 
physicians. This disorder usually has a disabling effect on the patient’s emotional well being, 
social interaction, work productivity, etc. Many analgesic drugs, such as opiods, NSAID, 
tricyclic antidepressants, are widely used in the management of chronic pain. However, the 
major problem with all these drugs is represented by the loss of analgesic efficacy because of the 
induction oftolerance (Payne et al., 1986). 
The development of tolerance with repeated use is a characteristic feature of all the opioid 
drugs. Tolerance is a physiological response seen in all patients. In particular, spinal opioid use 
for chronic pain has caused major clinical problems since the high concentrations of opioid in the 
cerebrospinal fluid create receptor tolerance, especially if those concentrations exceed the level 
required to alleviate pain (Twycross and McQuay, 1990). 
Twice daily administrations for 2 weeks of HI-antihistaminics to mice did not cause 
development of tolerance to their analgesic effect representing the first observation of persistent 
antinociception in animals. In contrast, in accordance with results obtained in humans, subacute 
treatment for 2 weeks completely abolished analgesia induced by morphine. Moreover, the 
animals’ sensitivity to the antinociception induced by baclofen and oxotremorine was 
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completely lost following subacute treatment. These data indicate that the experimental schedule 
used represents an appropriate animal model to unmask the ability to induce tolerance by long- 
term treatment with analgesic drugs. Therefore, the lack of tolerance observed with the 
antihistaminics cannot be imputable to an inadequate experimental paradigm, but represents a 
characteristic feature of this category of drugs. This property of the H1-antihistaminics is 
supported by the fact that repeated administration of hydroxyzine did not cause tolerance to 
sedation, which is another central effect produced by HI-antihistaminics (Goetz et al., 1989). 
Nor did, H,-antihistaminics cause tolerance by peripheral effects to develop. Wheal-and-flare 
suppression in the skin test reactivity to histamine or allergen, as well as efficacy in ragweed 
pollen-induced rhinoconjunctivitis, were not suppressed by long-term loratadine and terfenedine 
treatment (Bousquet et al. 1990; Simons et al., 1988; Juniper et al., 1988). 
Repeated administration of HI-antihistaminics did not alter animals’ gross behavior. By 
day 14 animals’ motor coordination was unmodified, as shown by the rota-rod test, indicating 
beyond doubt that the increase in licking latency, as well as the reduction in abdominal 
constrictions observed were not due to the animal’s altered viability. 
Considering that the major drawback of long-term treatment with analgesicdrugs consists 
of the development of tolerance, H1 antagonists could represent a promising pharmacological 
approach to the management of chronic pain. 
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